Dako and Cell Signaling Technologies Partner on Cancer CDx

Danish diagnostics maker Dako is partnering with Cell Signaling Technologies to create companion diagnostics for cancer treatments. The arrangement calls for CST to provide antibodies for Dako’s diagnostics.

The companion diagnostics will be used to better match cancer patients with appropriate treatment, said Jacob Thaysen, president of Agilent Technologies’ Diagnostics and Genomics Group. Agilent acquired Dako in 2012.

Dako has previously teamed up with Pfizer, AstraZeneca, Bristol-Myers Squibb, Merck, Amgen and Eli Lilly to create companion diagnostics.

Financial terms of the collaboration were not disclosed. — Kellen Owings